SOCS1 and Lymphadenopathy: In this study, we show that administration of peptide variants of SOCS1-KIR to MRL/lpr mice mitigated skin lesions, lymphadenopathy, anti-dsDNA IgG levels, and reduced lupus associated kidney pathology.